NIKKEI 225
29,393.66 +178.14 (+0.61%) HANG SENG
26,011.84 +224.63 (+0.87%) GOLD FUTURES
1,772.40 +1.90 (+0.11%) DOW
35,457.31 +198.70 (+0.56%) BTC-GBP
46,283.57 +1,287.44 (+2.86%) CMC Crypto 200
1,480.98 +17.63 (+1.20%)
Biogen Inc. (BIIB.MX)
| Previous close | 5,704.00 |
| Open | 5,482.97 |
| Bid | 5,400.00 x 100 |
| Ask | 0.00 x 100 |
| Day's range | 5,420.00 - 5,482.97 |
| 52-week range | 4,766.00 - 8,700.00 |
| Volume | 64 |
| Avg. volume | 227 |
| Market cap | 859.758B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 13.89 |
| EPS (TTM) | 390.17 |
| Earnings date | 19 Oct 2021 - 25 Oct 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
CAMBRIDGE, Mass., October 19, 2021--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced their plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone, an investigational two-week, once-daily therapeutic in the second half of 2022. The planned initial submission package will seek approval of zuranolone for the treatment of major depressive disorder (MDD) and an additional filing for postpartum depression (PPD) is
- Zacks
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports third-quarter earnings.
- Zacks
Biogen's (BIIB) Tofersen Reports Mixed Data From ALS Study
Biogen's (BIIB) phase III study evaluating tofersen for ALS with SOD1 mutation fails to meet the primary endpoint of the study. However, the study shows signs of reduced disease progression with tofersen.
